<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.14" epochem-id="EPOCHEM:NEW:COMPOUND:1199" name="glucosaminylmuramic acid" comment="" chebi-id="WO2007045192:885915" relevant="true">Glucosaminylmuramic acid</ne> derivatives
Technical field of the invention
The invention deals with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.15" epochem-id="EPOCHEM:NEW:COMPOUND:1199" name="glucosaminylmuramic acid" comment="" chebi-id="WO2007045192:885915" relevant="true">glucosaminylmuramic acid</ne> (<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.16" epochem-id="EPOCHEM:NEW:COMPOUND:1200" name="2-amino-2-deoxy-[beta]-D-gluco-pyranosyl -(l-&gt;4)-iV-acetylmuramicacid" comment="2-amino-2-deoxy-[beta]-D-gluco-pyranosyl -(1-&gt;4)-N-acetylmuramicacid" chebi-id="WO2007045192:674439" relevant="true">2-amino-2-deoxy-[beta]-D-gluco- pyranosyl-(l-&gt;4)-iV-acetylmuramic acid</ne>) derivatives, method of their synthesis, and their use for the synthesis of <ne type="LIGAND" id="WO2007045192.HC.ligand-names.1" epochem-id="EPOCHEM:NEW:LIGAND:312" name="glucosaminylmuramyl" comment="" chebi-id="WO2007045192:482973" relevant="false">glucosaminylmuramyl</ne> glycopeptides, i.e. <ne id="WO2007045192.HC.class-names.4" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> analogues of <ne id="WO2007045192.HC.class-names.25" epochem-id="EPOCHEM:NEW:CLASS:997" name="muramyl glycopeptides" comment="" chebi-id="WO2007045192:575300" relevant="false" type="CLASS">muramyl glycopeptides</ne>.
Background of the invention
Immunopharmaceutics represent a new group of drugs that already have an irreplaceable role in modern clinical practice. Disorders of the organism immune capacity due to negative changes in the environment, an increased occurrence of pathogenic microorganisms resistant to antibiotics, and infections damaged immunity (e.g. AIDS) as well as a frequent application of immunosuppressive therapeutic procedures such as radio- and chemotherapy of tumor diseases, just as following transplantations, present a serious medical problem. The present tendency to replace live vaccines by safer semi-synthetic, recombinant, and synthetic ones requires new structurally defined adjuvants. Therefore, considerable attention is devoted to the development of substances with immunostimulatory activity with the aim to obtain a) safe, structurally defined adjuvants for protein, <ne id="WO2007045192.HC.class-names.88" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> and DNA vaccines, b) stimulators of nonspecific antiinfectious and antitumor immunity, and c) stimulators of hemopoiesis.
Important representatives of such compounds are <ne id="WO2007045192.HC.class-names.26" epochem-id="EPOCHEM:NEW:CLASS:997" name="muramyl glycopeptides" comment="" chebi-id="WO2007045192:575300" relevant="false" type="CLASS">muramyl glycopeptides</ne> that are derived from <ne id="WO2007045192.HC.class-names.102" epochem-id="EPOCHEM:NEW:CLASS:1151" name="peptidoglycan" comment="" chebi-id="CHEBI:8005" relevant="false" type="CLASS">peptidoglycan</ne> fragments of bacterial cell wall, i.e. compounds derived from the minimal immunoadjuvant unit, "<ne id="WO2007045192.HC.class-names.58" epochem-id="EPOCHEM:NEW:CLASS:1000" name="muramyldipeptide" comment="muramyl dipeptide" chebi-id="WO2007045192:774301" relevant="false" type="CLASS">muramyl dipeptide</ne>" (<ne id="WO2007045192.HC.class-names.50" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne>), and basic repeating <ne id="WO2007045192.HC.class-names.5" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne>-<ne id="WO2007045192.HC.class-names.76" epochem-id="EPOCHEM:NEW:CLASS:1006" name="dipeptide" comment="" chebi-id="WO2007045192:217448" relevant="false" type="CLASS">dipeptide</ne> unit, "<ne id="WO2007045192.HC.class-names.30" epochem-id="EPOCHEM:NEW:CLASS:998" name="glucosaminyl-muramyl-dipeptide" comment="" chebi-id="WO2007045192:354808" relevant="false" type="CLASS">glucosaminyl-muramyl-dipeptide</ne>" (<ne id="WO2007045192.HC.class-names.31" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>).
During the past three decades many analogues of <ne id="WO2007045192.HC.class-names.51" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne> and <ne id="WO2007045192.HC.class-names.32" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> were synthesized in order to increase the specificity of therapeutic activity and to suppress undesired side effects, especially pyrogenicity.
This effort led to compounds interesting for pharmaceutical industry (for review see ref. &lt;M&gt;). From <ne id="WO2007045192.HC.class-names.52" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne> derived compounds, therapeutic Romurtid(TM) (<ne id="WO2007045192.HC.class-names.53" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne>-Lys-L-18), based on <ne id="WO2007045192.HC.class-names.54" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne> molecule prolonged in the <ne id="WO2007045192.HC.class-names.89" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> part by Lys substituted with <ne type="LIGAND" id="WO2007045192.HC.ligand-names.22" epochem-id="EPOCHEM:NEW:LIGAND:546" name="stearoyl" comment="" chebi-id="CHEBI:26753" relevant="false">stearoyl</ne> residue, is in the most progressed phase of development. Romurtid(TM) is less pyrogenic than <ne id="WO2007045192.HC.class-names.55" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne> and successfully passed clinical trials. Principal practical application is stimulation of hemopoiesis in patients after radiotherapy or chemotherapy&lt;3"5&gt;. Acceleration of neutrophil number normalization in periphery blood is important in order to suppress the risk of infection in immunosuppressed patients&lt;6&gt;'&lt;7&gt;. Romurtid(TM) is also able to increase natural immunity against viral&lt;8&gt; and bacterial&lt;9&gt;'&lt;10&gt; infections and tumor growth&lt;11&gt;.
<ne id="WO2007045192.HC.class-names.33" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>, in comparison with <ne id="WO2007045192.HC.class-names.56" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne>, has higher immunoadjuvant activity and lower pyrogenicity.
Hence, the compounds derived from <ne id="WO2007045192.HC.class-names.34" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> are more perspective potential immunotherapeutics than compounds derived from <ne id="WO2007045192.HC.class-names.57" epochem-id="EPOCHEM:NEW:CLASS:964" name="MDP" comment="" chebi-id="WO2007045192:560321" relevant="false" type="CLASS">MDP</ne>&lt;2&gt;. <ne id="WO2007045192.HC.class-names.35" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>-based compound <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.233" epochem-id="EPOCHEM:NEW:COMPOUND:2051" name="Likopid" comment="" chebi-id="WO2007045192:740473" relevant="false">Likopid</ne>(TM) is the first immunotherapeutic of the muramyl <ne id="WO2007045192.HC.class-names.104" epochem-id="EPOCHEM:NEW:CLASS:1153" name="glycopeptide" comment="" chebi-id="WO2007045192:573126" relevant="false" type="CLASS">glycopeptide</ne> type introduced to the clinical practice. <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.234" epochem-id="EPOCHEM:NEW:COMPOUND:2051" name="Likopid" comment="" chebi-id="WO2007045192:740473" relevant="false">Likopid</ne>(TM) was developed and registered by a Russian company Peptek as an immunotherapeutic with broad applicability, e.g. immunostimulation and prevention of infections complicating post-traumatic, post-operative, post-chemotherapeutic and post- radiotherapeutic patienthood&lt;12&gt;. Other areas are treatment of infectious diseases, as tuberculosis, human cervical papilomavirus, ophthalmic herpetic infections, psoriasis and treatment of ulcerous and inflammation processes. <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.235" epochem-id="EPOCHEM:NEW:COMPOUND:2051" name="Likopid" comment="" chebi-id="WO2007045192:740473" relevant="false">Likopid</ne>(TM) can be used alone or in combination with antibiotics and antivirotics&lt;13&gt; for treatment of infectious diseases. Side effects are associated with pyrogenicity that stems from the active component <ne id="WO2007045192.HC.class-names.36" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>.
Company ImmunoTherapeutics, Inc., North Dacota, USA, is developing lipophilic analogues of <ne id="WO2007045192.HC.class-names.37" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>, e.g. "<ne id="WO2007045192.HC.class-names.59" epochem-id="EPOCHEM:NEW:CLASS:1001" name="disaccharidetripeptide-glyceroldipalmitate" comment="" chebi-id="WO2007045192:404495" relevant="false" type="CLASS">disaccharidetripeptide-glyceroldipalmitate</ne>" (<ne id="WO2007045192.HC.class-names.60" epochem-id="EPOCHEM:NEW:CLASS:1002" name="DTP-GDP" comment="" chebi-id="WO2007045192:439498" relevant="false" type="CLASS">DTP-GDP</ne>), modified in the carboxy-terminal part by <ne type="LIGAND" id="WO2007045192.HC.ligand-names.12" epochem-id="EPOCHEM:NEW:LIGAND:545" name="glycerol-dipalmitate residue" comment="" chebi-id="WO2007045192:705048" relevant="false">glycerol-dipalmitate residue</ne>, and structurally related <ne id="WO2007045192.HC.class-names.65" epochem-id="EPOCHEM:NEW:CLASS:1004" name="GMTP- N-DPG" comment="" chebi-id="WO2007045192:382659" relevant="false" type="CLASS">GMTP- N-DPG</ne>, modified in the carboxy-terminal part of the <ne id="WO2007045192.HC.class-names.90" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> chain by <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.19" epochem-id="EPOCHEM:NEW:COMPOUND:1202" name="dipalmitoylpropylarnide" comment="" chebi-id="WO2007045192:229045" relevant="false">dipalmitoylpropylarnide</ne> residue. <ne id="WO2007045192.HC.class-names.61" epochem-id="EPOCHEM:NEW:CLASS:1002" name="DTP-GDP" comment="" chebi-id="WO2007045192:439498" relevant="false" type="CLASS">DTP-GDP</ne> was proposed as potential immunotherapeutic of tumor diseases&lt;14&gt;. The compound applied in liposomes is active in the therapy of liver tumors metastases &lt;5&gt;. <ne id="WO2007045192.HC.class-names.62" epochem-id="EPOCHEM:NEW:CLASS:1002" name="DTP-GDP" comment="" chebi-id="WO2007045192:439498" relevant="false" type="CLASS">DTP-GDP</ne> passed successfully phase II of clinical trials, but is strongly pyrogenic&lt;15&gt;. Its main side effects, besides pyrogenicity, are shivers, nausea and hypotension. <ne id="WO2007045192.HC.class-names.66" epochem-id="EPOCHEM:NEW:CLASS:1004" name="GMTP- N-DPG" comment="" chebi-id="WO2007045192:382659" relevant="false" type="CLASS">GMTP-N-DPG</ne> is a perspective adjuvans for cellular immunity usable for construction of new generation vaccines against some serious infectious diseases (AIDS, tuberculosis, malaria)&lt;16&gt;'&lt;17&gt;. Some of the above mentioned analogues are part of produced adjuvants. As examples can be given Gerbu Adjuvant(TM), containing <ne id="WO2007045192.HC.class-names.38" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> (CC Biotech Corporation, USA), ImmTher(TM), containing DTP-GDP5 and Theramide (TM), containing <ne id="WO2007045192.HC.class-names.103" epochem-id="EPOCHEM:NEW:CLASS:1152" name="DTP-DPP" comment="" chebi-id="WO2007045192:366560" relevant="false" type="CLASS">DTP-DPP</ne> (<ne id="WO2007045192.HC.class-names.67" epochem-id="EPOCHEM:NEW:CLASS:1004" name="GMTP- N-DPG" comment="" chebi-id="WO2007045192:382659" relevant="false" type="CLASS">GMTP-N- DPG</ne>) (ImmunoTherapeutics, USA); ref.&lt;18&gt;.
The accessibility of the carbohydrate component is the main problem in the synthesis of <ne id="WO2007045192.HC.class-names.39" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>-derived <ne id="WO2007045192.HC.class-names.64" epochem-id="EPOCHEM:NEW:CLASS:1003" name="murarnyl glycopeptides" comment="muramyl glycopeptides" chebi-id="WO2007045192:6801" relevant="false" type="CLASS">murarnyl glycopeptides</ne>. The synthesis of oligosaccharides represents a challenging task, especially as for the sequences containing <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.20" epochem-id="EPOCHEM:COMPOUND:1933" name="D-glucose" comment="" chebi-id="WO2007045192:81070" relevant="false">D-glucose</ne> units connected with [beta](l-&gt;4) glycosidic bond due to a low reactivity of the OH(4) group&lt;19"23&gt;.
Known synthetic approaches of <ne id="WO2007045192.HC.class-names.6" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> <ne id="WO2007045192.HC.class-names.40" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> component represent a challenging process due to many synthetic steps and associated low affectivity. These syntheses can be divided into three groups (according to the glycosyl acceptor used for glycosylation reaction representing a key step in <ne id="WO2007045192.HC.class-names.7" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> unit synthesis): a) glycosylation with acyclic precursor of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.1" epochem-id="EPOCHEM:COMPOUND:260" name="muramic acid" comment="" chebi-id="CHEBI:28118" relevant="false">muramic acid</ne>&lt;24&gt;'&lt;25&gt;, b) glycosylation with cyclic precursor of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.2" epochem-id="EPOCHEM:COMPOUND:260" name="muramic acid" comment="" chebi-id="CHEBI:28118" relevant="false">muramic acid</ne>&lt;26"28&gt;, and c) glycosylation with cyclic derivative of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.3" epochem-id="EPOCHEM:COMPOUND:260" name="muramic acid" comment="" chebi-id="CHEBI:28118" relevant="false">muramic acid</ne>&lt;29"33&gt;. Therefore semisynthetic, in addition to de novo synthetic, approach is applied in the field of <ne id="WO2007045192.HC.class-names.41" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> and its analogues synthesis, too.
The sugar component preparation is based on a biotechnological process of preparation of bacterial mass by fermentation, by partial enzymatic hydrolysis of bacterial walls and difficult isolation of <ne id="WO2007045192.HC.class-names.8" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> unit by chromatographic techniques. The obtained <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.21" epochem-id="EPOCHEM:NEW:COMPOUND:1203" name="2-acetamido-2- deoxy-[beta]-D-glucopyranosyl(l-&gt;4)N-acetylmuramic acid" comment="2-acetamido-2- deoxy-[beta]-D-glucopyranosyl(1-&gt;4)N-acetylmuramic acid" chebi-id="WO2007045192:859793" relevant="false">2-acetamido-2- deoxy-[beta]-D-glucopyranosyl(l-&gt;4)N-acetylmuramic acid</ne> (<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.23" epochem-id="EPOCHEM:NEW:COMPOUND:1204" name="[beta]-D-Glc[Nu]Ac(l-&gt;4)Mur[Nu]Ac" comment="[beta]-D-Glc[Nu]Ac(1-&gt;4)Mur[Nu]Ac" chebi-id="WO2007045192:222058" relevant="false">[beta]-D-Glc[Nu]Ac(l-&gt;4)Mur[Nu]Ac</ne>) is then condensed with the <ne id="WO2007045192.HC.class-names.91" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> component&lt;17&gt;'&lt;34"36&gt;. The semisynthetic approach is applied as by a Russian company Peptek for the preparation of the active component of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.236" epochem-id="EPOCHEM:NEW:COMPOUND:2051" name="Likopid" comment="" chebi-id="WO2007045192:740473" relevant="false">Likopid</ne>(TM) (<ne id="WO2007045192.HC.class-names.42" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>) and by ImmunoTherapeutics, Inc., USA, for preparation of <ne id="WO2007045192.HC.class-names.43" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> analogues (<ne id="WO2007045192.HC.class-names.63" epochem-id="EPOCHEM:NEW:CLASS:1002" name="DTP-GDP" comment="" chebi-id="WO2007045192:439498" relevant="false" type="CLASS">DTP-GDP</ne> and <ne id="WO2007045192.HC.class-names.68" epochem-id="EPOCHEM:NEW:CLASS:1004" name="GMTP- N-DPG" comment="" chebi-id="WO2007045192:382659" relevant="false" type="CLASS">GMTP-N-DPG</ne>) modified in carboxy terminal part of the <ne id="WO2007045192.HC.class-names.92" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> chain by lipophilic residue. In spite of illusive simple semisynthetic approach, their disadvantages are poor reproducibility and necessity of standardization of the biotechnological production process of <ne id="WO2007045192.HC.class-names.9" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> component. At the same time, reproducibility and standardization of production processes are the main criteria for the production of drugs and their substances.
A limiting factor for introduction of <ne id="WO2007045192.HC.class-names.44" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>-based therapeutics into the practice is complicated accessibility of the <ne id="WO2007045192.HC.class-names.10" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> component, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.24" epochem-id="EPOCHEM:NEW:COMPOUND:1205" name="2-acetamido-2-deoxy-[beta]-D- glucopyranosyl(l-&gt;4)iV-acetylmuraniic acid" comment="2-acetamido-2-deoxy-[beta]-D- glucopyranosyl(1-&gt;4)-N-acetylmuraniic acid" chebi-id="WO2007045192:823068" relevant="true">2-acetamido-2-deoxy-[beta]-D- glucopyranosyl(l-&gt;4)iV-acetylmuraniic acid</ne> (<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.25" epochem-id="EPOCHEM:NEW:COMPOUND:1206" name="[beta]-D-GlcNAc(l-&quot;4)MurNAc" comment="" chebi-id="WO2007045192:411390" relevant="false">[beta]-D-GlcNAc(l-"4)MurNAc</ne>), and their derivatives, respectively. Present invention solves this problem by elaboration of effective synthesis of <ne id="WO2007045192.HC.class-names.11" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon enabling reasonable synthesis of <ne id="WO2007045192.HC.class-names.45" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>-based <ne id="WO2007045192.HC.class-names.27" epochem-id="EPOCHEM:NEW:CLASS:997" name="muramyl glycopeptides" comment="" chebi-id="WO2007045192:575300" relevant="false" type="CLASS">muramyl glycopeptides</ne> as well as <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.22" epochem-id="EPOCHEM:NEW:COMPOUND:1203" name="2-acetamido-2- deoxy-[beta]-D-glucopyranosyl(l-&gt;4)N-acetylmuramic acid" comment="2-acetamido-2- deoxy-[beta]-D-glucopyranosyl(1-&gt;4)N-acetylmuramic acid" chebi-id="WO2007045192:859793" relevant="false">2-acetamido-2-deoxy-[beta]-D-glucopyranosyl(l-&gt;4)N-acetylmuramic acid</ne> itself.
Detailed description of the invention
a) One aspect of the invention relates to <ne id="WO2007045192.HC.class-names.12" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon of the following formula I
</P>
<P>[0014]
EMI5.1
b) Other aspect of the invention relates to synthetic pathway of preparation of <ne id="WO2007045192.HC.class-names.13" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon of formula I.
The synthesis of the compound I starts with <ne type="ONT" id="WO2007045192.HC.class-names.1" epochem-id="EPOCHEM:NEW:CLASS:285" name="glycosyl donor" comment="" chebi-id="WO2007045192:220621" relevant="false">glycosyl donor</ne>, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.26" epochem-id="EPOCHEM:NEW:COMPOUND:1207" name="3,4,6-tri-0-acetyl-2- deoxy-2-phthalimido-[beta]-D-glucopyranosyl bromide" comment="" chebi-id="WO2007045192:208103" relevant="true">3,4,6-tri-0-acetyl-2- deoxy-2-phthalimido-[beta]-D-glucopyranosyl bromide</ne>, obtained in two steps synthesis according to art&lt;37&gt;'&lt;38&gt;, from commercially available <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.27" epochem-id="EPOCHEM:NEW:COMPOUND:1208" name="D-glucosamine hydrochloride" comment="" chebi-id="WO2007045192:308" relevant="false">D-glucosamine hydrochloride</ne>. As glycosyl acceptor, a <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.4" epochem-id="EPOCHEM:COMPOUND:260" name="muramic acid" comment="" chebi-id="CHEBI:28118" relevant="false">muramic acid</ne> derivative, i.e. <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.28" epochem-id="EPOCHEM:NEW:COMPOUND:1209" name="benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[l-(R)-(metho- xycarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[1-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:904347" relevant="true">benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[l-(R)-(metho- xycarbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> of formula II
</P>
<P>[0017]
EMI5.2
the synthesis of which is also a part of the invention, is used.
Glycosyl acceptor II synthesis starts from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.29" epochem-id="EPOCHEM:NEW:COMPOUND:1210" name="benzyl-2-acetamido-2-deoxy-4,6-O- isopropylidene-[alpha]-D-glucopyranoside" comment="" chebi-id="WO2007045192:260944" relevant="false">benzyl-2-acetamido-2-deoxy-4,6-O- isopropylidene-[alpha]-D-glucopyranoside</ne> lll
EMI6.1
which is obtained in two synthetic steps as given in the art&lt;39&gt; from commercially available <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.30" epochem-id="EPOCHEM:NEW:COMPOUND:1211" name="N- acetyl-D-glucosamine" comment="" chebi-id="WO2007045192:938795" relevant="false">N- acetyl-D-glucosamine</ne>.
</P>
<P>3-0-Alkylation of compound III on treatment with racemic <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.31" epochem-id="EPOCHEM:NEW:COMPOUND:1212" name="bromopropionic acid" comment="" chebi-id="WO2007045192:591149" relevant="false">bromopropionic acid</ne> or its (S)-stereoisomer in a <ne type="ONT" id="WO2007045192.HC.class-names.78" epochem-id="EPOCHEM:NEW:CLASS:1007" name="polar aprotic solvent" comment="" chebi-id="WO2007045192:646855" relevant="false">polar aprotic solvent</ne> and in the presence of a strong base (with advantage in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.35" epochem-id="EPOCHEM:NEW:COMPOUND:1213" name="dioxan" comment="" chebi-id="WO2007045192:460233" relevant="false">dioxan</ne> or <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.38" epochem-id="EPOCHEM:NEW:COMPOUND:1214" name="tetrahydrofurane" comment="" chebi-id="WO2007045192:136522" relevant="false">tetrahydrofurane</ne> in the presence of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.39" epochem-id="EPOCHEM:NEW:COMPOUND:748" name="sodium hydride" comment="" chebi-id="WO2007045192:78112" relevant="false">sodium hydride</ne>) and the following esterification of the produced acid with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.42" epochem-id="EPOCHEM:NEW:COMPOUND:1215" name="diazomethane" comment="" chebi-id="WO2007045192:503048" relevant="false">diazomethane</ne> or of its salt with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.45" epochem-id="EPOCHEM:NEW:COMPOUND:1216" name="methyl iodide" comment="" chebi-id="CHEBI:39282" relevant="false">methyl iodide</ne> affords <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.47" epochem-id="EPOCHEM:NEW:COMPOUND:1217" name="benzyl-2-acetamido-2-deoxy-4,6-O-isopropylidene-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]- D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-4,6-O-isopropylidene-3-O-[1-(R)-(methoxycarbonyl)ethyl]-[alpha]- D-glucopyranoside" chebi-id="WO2007045192:895020" relevant="false">benzyl-2-acetamido-2-deoxy-4,6-O-isopropylidene-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]- D-glucopyranoside</ne> IV.
</P>
<P>[0022]
EMI6.2
IV
The acetal protecting group in compound IV is removed by acidic hydrolysis, advantageously by action of ion-exchanger Dowex 50 in H&lt;+&gt; cycle in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.48" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> or by heating in aqueous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.64" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>, affording <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.78" epochem-id="EPOCHEM:NEW:COMPOUND:1218" name="benzyl-2-acetamido-2-deoxy-3-O-[l-(R)- (methoxycarbonyl)ethyl] -[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-3-O-[1-(R)- (methoxycarbonyl)ethyl] -[alpha]-D-glucopyranoside" chebi-id="WO2007045192:274287" relevant="false">benzyl-2-acetamido-2-deoxy-3-O-[l-(R)- (methoxycarbonyl)ethyl] -[alpha]-D-glucopyranoside</ne> V.
</P>
<P>[0025]
EMI6.3
V
Partial benzoylation of compound V, in advantage with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.240" epochem-id="EPOCHEM:NEW:COMPOUND:2052" name="benzoylimidazole" comment="" chebi-id="WO2007045192:497595" relevant="false">benzoylimidazole</ne> in dichloro- methane, affords glycosyl acceptor of formula II.
EMI7.1
Reaction of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.79" epochem-id="EPOCHEM:NEW:COMPOUND:1219" name="3,4,6-tri-(9-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl bromide" comment="" chebi-id="WO2007045192:875787" relevant="false">3,4,6-tri-(9-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl bromide</ne>, as <ne type="ONT" id="WO2007045192.HC.class-names.2" epochem-id="EPOCHEM:NEW:CLASS:285" name="glycosyl donor" comment="" chebi-id="WO2007045192:220621" relevant="false">glycosyl donor</ne>, with glycosyl acceptor II in aprotic solvent promoted by heavy metal salts (in advantage in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.80" epochem-id="EPOCHEM:COMPOUND:5443" name="dichloromethane" comment="" chebi-id="CHEBI:15767" relevant="false">dichloromethane</ne> in the presence of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.81" epochem-id="EPOCHEM:NEW:COMPOUND:1220" name="silver trifluoromethanesulfonate" comment="" chebi-id="WO2007045192:662680" relevant="false">silver trifluoromethanesulfonate</ne> as promotor) afforded <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.82" epochem-id="EPOCHEM:NEW:COMPOUND:1221" name="benzyl-3 ,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl- (1 -&gt;4)-2-acetamido-6-(9-benzoyl-2-deoxy-3 -O- [ 1 -(R)-(methoxycarbonyl)ethyl] -[alpha]-D-gluco- pyranoside" comment="" chebi-id="WO2007045192:417995" relevant="true">benzyl-3 ,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl- (1 -&gt;4)-2-acetamido-6-(9-benzoyl-2-deoxy-3 -O- [ 1 -(R)-(methoxycarbonyl)ethyl] -[alpha]-D-gluco- pyranoside</ne> VI.
</P>
<P>[0029]
EMI7.2
Vl
Sequential removing of protecting groups sensitive to alkali (i.e. <ne type="LIGAND" id="WO2007045192.HC.ligand-names.26" epochem-id="EPOCHEM:NEW:LIGAND:160" name="acetyl" comment="" chebi-id="WO2007045192:727560" relevant="false">acetyl</ne>, <ne type="LIGAND" id="WO2007045192.HC.ligand-names.24" epochem-id="EPOCHEM:NEW:LIGAND:363" name="benzoyl" comment="" chebi-id="CHEBI:22733" relevant="false">benzoyl</ne>, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.83" epochem-id="EPOCHEM:NEW:COMPOUND:1222" name="methyl ester" comment="" chebi-id="WO2007045192:626249" relevant="false">methyl ester</ne> and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.85" epochem-id="EPOCHEM:COMPOUND:4551" name="phthalimide" comment="" chebi-id="CHEBI:38817" relevant="false">phthalimide</ne>), in advantage on treatment with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.87" epochem-id="EPOCHEM:NEW:COMPOUND:770" name="sodium methoxide" comment="" chebi-id="WO2007045192:61066" relevant="false">sodium methoxide</ne> in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.49" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.89" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.157" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>, and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.91" epochem-id="EPOCHEM:NEW:COMPOUND:1223" name="n-butylamine" comment="" chebi-id="WO2007045192:271610" relevant="false">n-butylamine</ne> in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.50" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>, respectively, affords <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.93" epochem-id="EPOCHEM:NEW:COMPOUND:1224" name="benzyl-2- amino-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl]- [alpha]-D-glucopyranoside" comment="benzyl-2- amino-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2-deoxy-3-O-[1-(R)-carboxyethyl]- [alpha]-D-glucopyranoside" chebi-id="WO2007045192:4293" relevant="true">benzyl-2- amino-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl]- [alpha]-D-glucopyranoside</ne> VII.
</P>
<P>[0031]
EMI7.3
VIl
iV-Acetylation of this compound VII with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.65" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> anhydride in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.158" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> affords <ne id="WO2007045192.HC.class-names.14" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon of formula I. c) The next aspect of the invention relates to the use of <ne id="WO2007045192.HC.class-names.15" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon I for synthesis of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.94" epochem-id="EPOCHEM:NEW:COMPOUND:1225" name="2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-JV-acetyl muramic acid" comment="2-Acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-N-acetyl muramic acid" chebi-id="WO2007045192:871173" relevant="true">2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-JV-acetyl muramic acid</ne> VIII.
</P>
<P>[0034]
EMI8.1
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.95" epochem-id="EPOCHEM:NEW:COMPOUND:1226" name="2-Acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-iV-acetyl muramic acid" comment="2-Acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-N-acetyl muramic acid" chebi-id="WO2007045192:368723" relevant="true">2-Acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-iV-acetyl muramic acid</ne> VIII is synthesized on hydrogenolytic removing of <ne type="LIGAND" id="WO2007045192.HC.ligand-names.23" epochem-id="EPOCHEM:NEW:LIGAND:547" name="ben2yl" comment="benzyl" chebi-id="WO2007045192:989717" relevant="false">ben2yl</ne> protecting groups, in advantage with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.108" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> <ne type="ONT" id="WO2007045192.HC.class-names.81" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> on charcoal in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.66" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>, from <ne id="WO2007045192.HC.class-names.16" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon of formula I.
d) The next aspect of the invention relates to the use of <ne id="WO2007045192.HC.class-names.17" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon I for the synthesis of <ne id="WO2007045192.HC.class-names.28" epochem-id="EPOCHEM:NEW:CLASS:997" name="muramyl glycopeptides" comment="" chebi-id="WO2007045192:575300" relevant="false" type="CLASS">muramyl glycopeptides</ne> based on <ne id="WO2007045192.HC.class-names.46" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> molecule of general formula IX
</P>
<P>[0037]
EMI8.2
in which X is <ne id="WO2007045192.HC.class-names.93" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> residue.
Reaction of <ne id="WO2007045192.HC.class-names.18" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon I with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.96" epochem-id="EPOCHEM:NEW:COMPOUND:1227" name="bis(pentafluorophenyl)carbonate" comment="" chebi-id="WO2007045192:981103" relevant="false">bis(pentafluorophenyl)carbonate</ne> in <ne type="ONT" id="WO2007045192.HC.class-names.79" epochem-id="EPOCHEM:NEW:CLASS:1007" name="polar aprotic solvent" comment="" chebi-id="WO2007045192:646855" relevant="false">polar aprotic solvent</ne> in the presence of base, with advantage in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.98" epochem-id="EPOCHEM:NEW:COMPOUND:1228" name="N,iV-dimethylformamide" comment="N, N-dimethylformamide" chebi-id="WO2007045192:973432" relevant="false">N,iV-dimethylformamide</ne> in the presence of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.99" epochem-id="EPOCHEM:NEW:COMPOUND:502" name="N-methylmorpholine" comment="" chebi-id="WO2007045192:843466" relevant="false">N-methylmorpholine</ne>, leads to <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.100" epochem-id="EPOCHEM:NEW:COMPOUND:1229" name="benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl- (1-&gt;-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="" chebi-id="WO2007045192:794684" relevant="true">benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl- (l-&gt;-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl)ethyl]-[alpha]-D-glucopyra- noside</ne> X.
</P>
<P>[0040]
EMI8.3
Reaction of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.104" epochem-id="EPOCHEM:NEW:COMPOUND:1232" name="pentafluorophenyl ester" comment="" chebi-id="WO2007045192:208229" relevant="false">pentafluorophenyl ester</ne> X with <ne id="WO2007045192.HC.class-names.94" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> component in <ne type="ONT" id="WO2007045192.HC.class-names.80" epochem-id="EPOCHEM:NEW:CLASS:1007" name="polar aprotic solvent" comment="" chebi-id="WO2007045192:646855" relevant="false">polar aprotic solvent</ne> in the presence of base, in advantage in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.101" epochem-id="EPOCHEM:COMPOUND:5016" name="N,N-dimethylformamide" comment="" chebi-id="CHEBI:17741" relevant="false">N,N-dimethylformamide</ne> in the presence of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.103" epochem-id="EPOCHEM:NEW:COMPOUND:1231" name="tri- ethylamine" comment="triethylamine" chebi-id="WO2007045192:858260" relevant="false">tri- ethylamine</ne> or <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.102" epochem-id="EPOCHEM:NEW:COMPOUND:1230" name="JV-methylmorpholine" comment="N-methylmorpholine" chebi-id="WO2007045192:598597" relevant="false">JV-methylmorpholine</ne>, affords protected <ne id="WO2007045192.HC.class-names.105" epochem-id="EPOCHEM:NEW:CLASS:1153" name="glycopeptide" comment="" chebi-id="WO2007045192:573126" relevant="false" type="CLASS">glycopeptide</ne> XI
</P>
<P>[0041]
EMI9.1
in which X is a <ne id="WO2007045192.HC.class-names.95" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> residue. For example, reaction with <ne id="WO2007045192.HC.class-names.70" epochem-id="EPOCHEM:NEW:CLASS:803" name="benzyl ester" comment="" chebi-id="WO2007045192:467443" relevant="false" type="CLASS">benzyl ester</ne> of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.106" epochem-id="EPOCHEM:NEW:COMPOUND:1234" name="L-alanyl-D-isoglu- tamine" comment="" chebi-id="WO2007045192:556750" relevant="false">L-alanyl-D-isoglu- tamine</ne> (available according to the ref.&lt;40&gt;) affords <ne id="WO2007045192.HC.class-names.71" epochem-id="EPOCHEM:NEW:CLASS:803" name="benzyl ester" comment="" chebi-id="WO2007045192:467443" relevant="false" type="CLASS">benzyl ester</ne> of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.105" epochem-id="EPOCHEM:NEW:COMPOUND:1233" name="iV-{2-O-[benzyl-2-acetamido- 2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)- lactoyl}-L-alanyl-D-isoglutamine" comment="N-{2-O-[benzyl-2-acetamido- 2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)- lactoyl}-L-alanyl-D-isoglutamine" chebi-id="WO2007045192:834059" relevant="true">iV-{2-O-[benzyl-2-acetamido- 2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)- lactoyl}-L-alanyl-D-isoglutamine</ne> (XI wherein X is <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.245" epochem-id="EPOCHEM:NEW:COMPOUND:2055" name="L-Ala-D-iso-Gln-OBn" comment="" chebi-id="WO2007045192:962811" relevant="false">L-Ala-D-iso-Gln-OBn</ne>).
Hydrogenolytic removing of <ne type="LIGAND" id="WO2007045192.HC.ligand-names.29" epochem-id="EPOCHEM:NEW:LIGAND:549" name="benzyl" comment="" chebi-id="CHEBI:22744" relevant="false">benzyl</ne> protecting group from reducing end of the saccharide part and protecting groups cleavable under these conditions from the <ne id="WO2007045192.HC.class-names.96" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> chain (<ne type="LIGAND" id="WO2007045192.HC.ligand-names.30" epochem-id="EPOCHEM:NEW:LIGAND:549" name="benzyl" comment="" chebi-id="CHEBI:22744" relevant="false">benzyl</ne> or <ne type="LIGAND" id="WO2007045192.HC.ligand-names.28" epochem-id="EPOCHEM:NEW:LIGAND:548" name="benzyloxycarbonyl" comment="" chebi-id="WO2007045192:609416" relevant="false">benzyloxycarbonyl</ne> groups) of <ne id="WO2007045192.HC.class-names.106" epochem-id="EPOCHEM:NEW:CLASS:1153" name="glycopeptide" comment="" chebi-id="WO2007045192:573126" relevant="false" type="CLASS">glycopeptide</ne> of general formula XI (with advantage with the use of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.109" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> <ne type="ONT" id="WO2007045192.HC.class-names.82" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> on charcoal in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.67" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>), affords <ne id="WO2007045192.HC.class-names.107" epochem-id="EPOCHEM:NEW:CLASS:1153" name="glycopeptide" comment="" chebi-id="WO2007045192:573126" relevant="false" type="CLASS">glycopeptide</ne> IX. For example, hydrogenolysis of <ne type="LIGAND" id="WO2007045192.HC.ligand-names.31" epochem-id="EPOCHEM:NEW:LIGAND:549" name="benzyl" comment="" chebi-id="CHEBI:22744" relevant="false">benzyl</ne> groups of <ne id="WO2007045192.HC.class-names.72" epochem-id="EPOCHEM:NEW:CLASS:803" name="benzyl ester" comment="" chebi-id="WO2007045192:467443" relevant="false" type="CLASS">benzyl ester</ne> of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.107" epochem-id="EPOCHEM:NEW:COMPOUND:1235" name="iV-{2-O-[benzyl-2-acetamido-2- deoxy-[beta]-D-glucopyranosyl-(l- &gt;4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)- lactoyl}-L-alanyl-D-isoglutamine" comment="N-{2-O-[benzyl-2-acetamido-2- deoxy-[beta]-D-glucopyranosyl-(1- &gt;4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)- lactoyl}-L-alanyl-D-isoglutamine" chebi-id="WO2007045192:204671" relevant="false">iV-{2-O-[benzyl-2-acetamido-2- deoxy-[beta]-D-glucopyranosyl-(l- &gt;4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)- lactoyl}-L-alanyl-D-isoglutamine</ne> (XI, wherein X is <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.246" epochem-id="EPOCHEM:NEW:COMPOUND:2055" name="L-Ala-D-iso-Gln-OBn" comment="" chebi-id="WO2007045192:962811" relevant="false">L-Ala-D-iso-Gln-OBn</ne>) with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.110" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> <ne type="ONT" id="WO2007045192.HC.class-names.83" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> on charcoal in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.68" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> affords <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.113" epochem-id="EPOCHEM:NEW:COMPOUND:1236" name="2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)- iV-acetylmuramyl-L-alanyl-D-isoglutamine" comment="2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)- N-acetylmuramyl-L-alanyl-D-isoglutamine" chebi-id="WO2007045192:528702" relevant="false">2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)- iV-acetylmuramyl-L-alanyl-D-isoglutamine</ne> (<ne id="WO2007045192.HC.class-names.47" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>) (IX, wherein X is <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.242" epochem-id="EPOCHEM:NEW:COMPOUND:2053" name="L-Ala-D-iso-Gln-OH" comment="" chebi-id="WO2007045192:637657" relevant="false">L-Ala-D-iso-Gln-OH</ne>).
The present invention is further illustrated by the following examples that are only illustrative and are not meant as any limitation of this invention. Examples
Example 1
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.40" epochem-id="EPOCHEM:NEW:COMPOUND:748" name="sodium hydride" comment="" chebi-id="WO2007045192:78112" relevant="false">Sodium hydride</ne> (9.0 g, 375 mmol) was added to a stirred solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.114" epochem-id="EPOCHEM:NEW:COMPOUND:1237" name="benzyl-2- acetamido-2-deoxy-4,6-0-isopropyliden-a-D-glucopyranoside" comment="benzyl-2- acetamido-2-deoxy-4,6-O-isopropyliden-αlpha-D-glucopyranoside" chebi-id="WO2007045192:178378" relevant="false">benzyl-2- acetamido-2-deoxy-4,6-0-isopropyliden-a-D-glucopyranoside</ne> III (24.6 g, 70 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.249" epochem-id="EPOCHEM:NEW:COMPOUND:2089" name="dioxane" comment="" chebi-id="CHEBI:46923" relevant="false">dioxane</ne> (270 ml) at room temperature and the mixture was heated for 2 h at 90 &lt;0&gt;C under stirring. The mixture was cooled down to room temperature, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.8" epochem-id="EPOCHEM:NEW:COMPOUND:1195" name="2-bromopropionic acid" comment="" chebi-id="WO2007045192:71889" relevant="true">2-bromopropionic acid</ne> (9.0 ml, 100 mmol) is added and the mixture is heated under stirring for 6 h at 65 [deg.]C. Excess hydride after cooling down to room temperature was decomposed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.159" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>; solid <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.115" epochem-id="EPOCHEM:COMPOUND:6719" name="carbon dioxide" comment="" chebi-id="CHEBI:16526" relevant="false">carbon dioxide</ne> was added to the mixture under Stirling followed by adding of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.160" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (20 ml). The mixture was evaporated in vacuum. The remaining residue is dissolved in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.161" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (450 ml), and the solution obtained was with ice neutralized with 5% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.162" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.202" epochem-id="EPOCHEM:NEW:COMPOUND:1252" name="sodium hydrogen sulphate" comment="" chebi-id="WO2007045192:866347" relevant="false">sodium hydrogen sulphate</ne> under stirring and cooling. Separated product was extracted with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.117" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne> (3 x 200 ml), the extract was dried with anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.188" epochem-id="EPOCHEM:NEW:COMPOUND:1243" name="magnesium sulphate" comment="" chebi-id="CHEBI:32599" relevant="false">magnesium sulphate</ne> and evaporated in vacuum to about 100 ml. A solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.43" epochem-id="EPOCHEM:NEW:COMPOUND:1215" name="diazomethane" comment="" chebi-id="WO2007045192:503048" relevant="false">diazomethane</ne> in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.125" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne> was added to evaporated residue under stirring and cooling with ice up to permanent yellow colour. After 30 minutes, the excess <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.44" epochem-id="EPOCHEM:NEW:COMPOUND:1215" name="diazomethane" comment="" chebi-id="WO2007045192:503048" relevant="false">diazomethane</ne> was decomposed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.69" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>, the mixture was evaporated in vacuum, and evaporated residue was chromatographed on <ne type="CHEMICAL" id="WO2007045192.HC.substance-names.1" epochem-id="EPOCHEM:NEW:SUBSTANCE:326" name="silica gel" comment="" chebi-id="WO2007045192:415358" relevant="false">silica gel</ne> column in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.118" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.131" epochem-id="EPOCHEM:NEW:COMPOUND:1238" name="toluen" comment="" chebi-id="CHEBI:17578" relevant="false">toluen</ne> mixture (2:1).
Homogenous fraction with higher RF was evaporated in vacuum, and the obtained crystalline residue (19.6 g, 64,0 %), <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.132" epochem-id="EPOCHEM:NEW:COMPOUND:1239" name="benzyl-2-acetamido-2-deoxy-4,6-O-isopropyliden-3-O- [l-(R)-(methoxykarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="" chebi-id="WO2007045192:953053" relevant="true">benzyl-2-acetamido-2-deoxy-4,6-O-isopropyliden-3-O- [l-(R)-(methoxykarbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> IV5 is without next purification deprotected (<ne type="LIGAND" id="WO2007045192.HC.ligand-names.11" epochem-id="EPOCHEM:NEW:LIGAND:315" name="isopropylidendioxy" comment="" chebi-id="WO2007045192:145503" relevant="false">isopropylidendioxy</ne> group is removed; see Examples 3 and 4). Crystallization of the residue from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.148" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.126" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.133" epochem-id="EPOCHEM:NEW:COMPOUND:1240" name="petrolether" comment="" chebi-id="WO2007045192:493034" relevant="false">petrolether</ne> mixture afforded an analytical sample of compound IV in the yield 76.5 %; m.p. 123 [deg.]C, [[alpha]]D + 139 (c 0.5, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.135" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>). For <ne type="FORMULA" id="WO2007045192.HC.formula-names.1" epochem-id="EPOCHEM:NEW:FORMULA:71" name="C22H31NOg" comment="C22H31NO8" chebi-id="WO2007045192:883980" relevant="false">C22H31NOg</ne> calculated: relative molecular mass 437.5, monoisotopic mass 437.2. FAB MS, mlz: 438.4 [M + H]&lt;+&gt;, 460.3 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.2" epochem-id="EPOCHEM:NEW:FORMULA:72" name="C22H3iNO8" comment="C22H31NO8" chebi-id="WO2007045192:481741" relevant="false">C22H3iNO8</ne> (437.5) calculated: 60.40 % C; 7.14 % H; 3.20 % N; found: 60.23 % C5 7.28 % H, 3.27 % N.
Evaporation of homogenous fraction with lower Rp value afforded 9.0 g (29.4 %) treacly residue, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.155" epochem-id="EPOCHEM:NEW:COMPOUND:1241" name="benzyl-2-acetamido-2-deoxy-4,6-&lt;9-isopropyliden-3-0-[ 1 -(S)-(methoxycar-bonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-4,6-O-isopropyliden-3-O-[ 1 -(S)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:680811" relevant="true">benzyl-2-acetamido-2-deoxy-4,6-&lt;9-isopropyliden-3-0-[ 1 -(S)-(methoxycar-bonyl)ethyl]-[alpha]-D-glucopyranoside</ne>, that crystallized on standing; m.p. 83 [deg.]C ; [[alpha]]o + 77 (c 0.5, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.136" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>). For C22H3INOs calculated: relative molecular mass 437.5, monoisotopic mass 437. FAB MS, mlz: 438.3 [M + H]&lt;+&gt;, 460.3 [M + Na]&lt;+&gt;. For C22H31NO8 (437.5) calculated: 60.40 % C; 7.14 % H; 3.20 % N; found: 60.51 % C, 7.23 % H5 3.18 % N.
Example 2
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.41" epochem-id="EPOCHEM:NEW:COMPOUND:748" name="sodium hydride" comment="" chebi-id="WO2007045192:78112" relevant="false">Sodium hydride</ne> suspended in mineral oil (60%, 1.2 g, 30 mmol) under <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.258" epochem-id="EPOCHEM:COMPOUND:7100" name="argon" comment="" chebi-id="CHEBI:33311" relevant="false">argon</ne> is washed with anhydrous hexane (3 x 5 ml,) and then suspended in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.237" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (10 ml). A solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.156" epochem-id="EPOCHEM:NEW:COMPOUND:1242" name="benzyl-2-acetamido-2-deoxy-4,6-O-isopropyliden-[alpha]-D- glucopyranoside" comment="" chebi-id="WO2007045192:944379" relevant="true">benzyl-2-acetamido-2-deoxy-4,6-(9-isopropyliden-[alpha]-D- glucopyranoside</ne> III (3.5 g, 10 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.238" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (20 ml) is added to the mixed suspension at room temperature and the mixture is heated for 2.5 h at 50 [deg.]C under stirring. A solution of (S)-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.9" epochem-id="EPOCHEM:NEW:COMPOUND:1195" name="2-bromopropionic acid" comment="" chebi-id="WO2007045192:71889" relevant="true">2-bromopropionic acid</ne> (1.1 ml, 12 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.239" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (10 ml) is added to the mixture during 2 hours and the mixture is heated for the next 8 h at 50 &lt;0&gt;C under stirring.
The mixture is cooled down to room temperature, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.46" epochem-id="EPOCHEM:NEW:COMPOUND:1216" name="methyl iodide" comment="" chebi-id="CHEBI:39282" relevant="false">methyl iodide</ne> (1.0 ml, 16 mmol) is added under stirring, and the mixture is stirred 24 h at room temperature. An excess hydride is decomposed with anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.51" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> (2.0 ml) and solid <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.116" epochem-id="EPOCHEM:COMPOUND:6719" name="carbon dioxide" comment="" chebi-id="CHEBI:16526" relevant="false">carbon dioxide</ne> and the resulted mixture is evaporated in vacuum. Evaporated residue is extracted with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.119" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne> (60 ml) and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.163" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (20 ml), organic phase is separated, washed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.164" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (2 x 20 ml), dried over anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.189" epochem-id="EPOCHEM:NEW:COMPOUND:1243" name="magnesium sulphate" comment="" chebi-id="CHEBI:32599" relevant="false">magnesium sulphate</ne>, and evaporated in vacuum. The evaporated residue is filtered through <ne type="CHEMICAL" id="WO2007045192.HC.substance-names.2" epochem-id="EPOCHEM:NEW:SUBSTANCE:326" name="silica gel" comment="" chebi-id="WO2007045192:415358" relevant="false">silica gel</ne> column in a mixture of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.120" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.149" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne> (2:1) and filtrate is evaporated in vacuum. Crystallization of the product from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.150" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.127" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.134" epochem-id="EPOCHEM:NEW:COMPOUND:1240" name="petrolether" comment="" chebi-id="WO2007045192:493034" relevant="false">petrolether</ne> mixture afforded 3.3 g (75.4 %) of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.192" epochem-id="EPOCHEM:NEW:COMPOUND:1244" name="benzyl-2-acetamido-2- deoxy-4,6-+O-isopropyliden-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="" chebi-id="WO2007045192:920242" relevant="true">benzyl-2-acetamido-2- deoxy-4,6-+O-isopropyliden-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> IV, identical with compound IV prepared in Example 1.
Example 3
Ion exchanger Dowex 50 in H&lt;+&gt; cycle (35 g) is added to a solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.193" epochem-id="EPOCHEM:NEW:COMPOUND:1245" name="benzyl-2- acetamido-2-deoxy-4,6-O-isopropyliden-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopy- ranoside" comment="benzyl-2- acetamido-2-deoxy-4,6-O-isopropyliden-3-O-[1-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopy- ranoside" chebi-id="WO2007045192:444847" relevant="true">benzyl-2- acetamido-2-deoxy-4,6-O-isopropyliden-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopy- ranoside</ne> IV (87.5 g, 200 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.52" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> (500 ml) and this mixture is stirred 2 h at room temperature. Reaction is monitored by TLC in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.137" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.53" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> system (10:1). Ion exchanger is filtered off, washed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.54" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> (2 x 400 ml), and the filtrate was f evaporated in vacuum.
Yield 78.7 g (99 %) of crystalline <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.194" epochem-id="EPOCHEM:NEW:COMPOUND:1246" name="benzyl-2-acetamido-2-deoxy~3-&lt;9- [l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-3-O- [1-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:445039" relevant="true">benzyl-2-acetamido-2-deoxy~3-&lt;9- [l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> V that was without any purification treated with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.244" epochem-id="EPOCHEM:NEW:COMPOUND:2054" name="benzoylimidazol" comment="" chebi-id="WO2007045192:537604" relevant="false">benzoylimidazol</ne> as given in Example 5. Crystallization of the product from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.121" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.128" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne> afforded an analytical sample of compound V; m.p. 134 - 138 [deg.]C, [[alpha]][pi] + 152 (c 0.5, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.138" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>); lit.&lt;41&gt; m.p. 130 - 132 &lt;0&gt;C, [[alpha]fo + 145 (c 1.0, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.139" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>); lit.&lt;42&gt; m.p. 120 - 122 [deg.]C, [[alpha]]D + 137 (c 0.9, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.140" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>); lit.&lt;43&gt; [[alpha]]D + 127 (c 1.0, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.141" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>). For C19H27NO8 calculated: relative molecular mass 397.4, monoisotopic mass 397.2. ESI MS, m/z: 420.3 [M + Na]&lt;+&gt;. For C19H27NO8 (397.4) calculated: 57.42 % C5 6.85 %H, 3.52 % N; found: 57.17 % C, 6.88 % H, 3.49 % N.
Example 4
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.195" epochem-id="EPOCHEM:NEW:COMPOUND:1247" name="Benzyl-2-acetamido-2-deoxy-4,6-(9-isopropyliden-3-0-[l-(R)-(methoxycarbonyl)- ethyl]-[alpha]-D-glucopyranoside" comment="Benzyl-2-acetamido-2-deoxy-4,6-(9-isopropyliden-3-O-[1-(R)-(methoxycarbonyl)- ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:511092" relevant="true">Benzyl-2-acetamido-2-deoxy-4,6-(9-isopropyliden-3-0-[l-(R)-(methoxycarbonyl)- ethyl]-[alpha]-D-glucopyranoside</ne> IV (8.8 g, 20 mmol) is heated under stirring in a mixture <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.70" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.165" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (1:1, 80 ml) for 30 min at 90 [deg.]C. The mixture was evaporated in vacuum. Evaporated residue was crystallized from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.122" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.129" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne> mixture. Yield 6.2 g (78.0 %) of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.196" epochem-id="EPOCHEM:NEW:COMPOUND:1248" name="benzyl-2-acetamido-2-deoxy-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopy- ranoside" comment="benzyl-2-acetamido-2-deoxy-3-O-[1-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopy- ranoside" chebi-id="WO2007045192:190656" relevant="true">benzyl-2-acetamido-2-deoxy-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopy- ranoside</ne> V, identical with compound V prepared according to example 3
Example 5
A solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.197" epochem-id="EPOCHEM:NEW:COMPOUND:1249" name="benzimidazol" comment="" chebi-id="CHEBI:36622" relevant="false">benzimidazol</ne> (37,9 g, 220 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.198" epochem-id="EPOCHEM:NEW:COMPOUND:1250" name="dichlormethane" comment="" chebi-id="WO2007045192:147135" relevant="false">dichlormethane</ne> (150 ml) was added to a mixed suspension of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.201" epochem-id="EPOCHEM:NEW:COMPOUND:1251" name="benzyl-2-acetamido-2-deoxy-3-0-[l-(R)-(methoxy- carbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-3-0-[1-(R)-(methoxy- carbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:584453" relevant="true">benzyl-2-acetamido-2-deoxy-3-0-[l-(R)-(methoxy- carbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> V (79.5 g, 200 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.199" epochem-id="EPOCHEM:NEW:COMPOUND:1250" name="dichlormethane" comment="" chebi-id="WO2007045192:147135" relevant="false">dichlormethane</ne> (500 ml) at 0 &lt;0&gt;C. A mixture is mixed for 30 min at 0 [deg.]C and then left to stand for at least 24 h at room temperature. The reaction process is monitored with TLC in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.142" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.55" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> system (10:1) and in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.151" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.123" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne> system (1:1).
The mixture is diluted with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.143" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne> (1000 ml) and the obtained solution is washed with 5% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.203" epochem-id="EPOCHEM:NEW:COMPOUND:1252" name="sodium hydrogen sulphate" comment="" chebi-id="WO2007045192:866347" relevant="false">sodium hydrogen sulphate</ne> in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.166" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (700 ml), <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.167" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (1000 ml) and saturated <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.204" epochem-id="EPOCHEM:COMPOUND:6837" name="sodium chloride" comment="" chebi-id="CHEBI:26710" relevant="false">sodium chloride</ne> solution in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.168" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (1000 ml), dried over anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.190" epochem-id="EPOCHEM:NEW:COMPOUND:1243" name="magnesium sulphate" comment="" chebi-id="CHEBI:32599" relevant="false">magnesium sulphate</ne> and evaporated in vacuum. Yield 99.3 g (99 %) of crystalline <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.206" epochem-id="EPOCHEM:NEW:COMPOUND:1253" name="benzyl-2-acetamido-6-0-benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbonyl)ethyl-[alpha]-D-glucopy- ranoside" comment="benzyl-2-acetamido-6-0-benzoyl-2-deoxy-3-O-[1-(R)-(methoxycarbonyl)ethyl-[alpha]-D-glucopy- ranoside" chebi-id="WO2007045192:850753" relevant="true">benzyl-2-acetamido-6-0-benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbonyl)ethyl-[alpha]-D-glucopy- ranoside</ne> II which is possible to use without any purification as glycosyl acceptor for <ne id="WO2007045192.HC.class-names.69" epochem-id="EPOCHEM:NEW:CLASS:1005" name="disacharide" comment="disaccharide" chebi-id="CHEBI:36233" relevant="false" type="CLASS">disacharide</ne> synthesis (see Example 6). Crystallization of the product from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.152" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.207" epochem-id="EPOCHEM:NEW:COMPOUND:771" name="heptane" comment="" chebi-id="CHEBI:43098" relevant="false">heptane</ne> mixture afforded an analytical sample of compound II in the yield of 90 %; m.p. 133-135 &lt;0&gt;C, [[alpha]]D + 85 (c 0,3, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.144" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>). Lit.&lt;44&gt; gives m.p. 98 - 100 &lt;0&gt;C, [[alpha]]D + 81 (c 1.0, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.145" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>). For <ne type="FORMULA" id="WO2007045192.HC.formula-names.3" epochem-id="EPOCHEM:NEW:FORMULA:73" name="C26H31NO9" comment="" chebi-id="WO2007045192:540917" relevant="false">C26H31NO9</ne> calculated: relative molecular mass 501.5, monoisotopic mass 501.2. FAB MS, m/z: 502.1 [M + H]&lt;+&gt;, 524.3 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.4" epochem-id="EPOCHEM:NEW:FORMULA:73" name="C26H31NO9" comment="" chebi-id="WO2007045192:540917" relevant="false">C26H31NO9</ne> (501.5) calculated: 62.27 % C, 6.23 % H, 2.79 % N; found: 62.58 % C, 6.45 % H, 2.66 % N.
Example 6
A mixture of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.208" epochem-id="EPOCHEM:NEW:COMPOUND:1254" name="benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbo- nyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[1-(R)-(methoxycarbo- nyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:502261" relevant="true">benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbo- nyl)ethyl]-[alpha]-D-glucopyranoside</ne> II (50.2 g, 100 mmol) and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.209" epochem-id="EPOCHEM:NEW:COMPOUND:1255" name="silver trifluoromethansulfonate" comment="" chebi-id="WO2007045192:450344" relevant="false">silver trifluoromethansulfonate</ne> (46.3 g, 180 mmol) is dried for 6 h at room temperature at 1.32 Pa. Anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.210" epochem-id="EPOCHEM:NEW:COMPOUND:1256" name="dichlorniethan" comment="dichlormethan" chebi-id="WO2007045192:319359" relevant="false">dichlorniethan</ne> (300 ml) is added to the mixture under <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.259" epochem-id="EPOCHEM:COMPOUND:7100" name="argon" comment="" chebi-id="CHEBI:33311" relevant="false">argon</ne>. The mixture is cooled down to -30 [deg.]C and during 1 h under stirring a solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.211" epochem-id="EPOCHEM:NEW:COMPOUND:1257" name="3,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyi-a- nosyl bromide" comment="3,4,6-tri-O-acetyl-2-deoxy-2-phtalimido-[beta]-D-glucopyi-a- nosyl bromide" chebi-id="WO2007045192:233230" relevant="true">3,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyi-a- nosyl bromide</ne> (89.7 g, 180 mmol) in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.200" epochem-id="EPOCHEM:NEW:COMPOUND:1250" name="dichlormethane" comment="" chebi-id="WO2007045192:147135" relevant="false">dichlormethane</ne> (300 ml) is added. The mixture is stirred for 1 h at -30 [deg.]C and for 2 h at -20 &lt;0&gt;C.
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.215" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">Pyridine</ne> (50 ml) is then added to the mixture under stirring at -20 &lt;0&gt;C and after rising of temperature to room temperature the mixture is diluted with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.146" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne> (1000 ml) and filtered. The filtrate is washed with cool (+4 [deg.]C) saturated aqueous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.212" epochem-id="EPOCHEM:NEW:COMPOUND:1258" name="sodium hydrogen carbonate" comment="" chebi-id="CHEBI:32139" relevant="false">sodium hydrogen carbonate</ne> (1000 ml), <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.169" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (1000 ml) and saturated aqueous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.205" epochem-id="EPOCHEM:COMPOUND:6837" name="sodium chloride" comment="" chebi-id="CHEBI:26710" relevant="false">sodium chloride</ne> solution (1000 ml), dried over anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.191" epochem-id="EPOCHEM:NEW:COMPOUND:1243" name="magnesium sulphate" comment="" chebi-id="CHEBI:32599" relevant="false">magnesium sulphate</ne>, evaporated at vacuum a co-distilled with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.153" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne> (2 x 500 ml) in vacuum. Column chromatography of the residue in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.124" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.154" epochem-id="EPOCHEM:COMPOUND:5618" name="toluene" comment="" chebi-id="CHEBI:17578" relevant="false">toluene</ne> (2:1) system afforded 78.1 g (85.0 %) of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.213" epochem-id="EPOCHEM:NEW:COMPOUND:1259" name="benzyl-3 ,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-( 1 -&gt;4)-2-acetamido-6-0- benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-3 ,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-( 1 -&gt;4)-2-acetamido-6-0- benzoyl-2-deoxy-3-O-[1-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:402111" relevant="true">benzyl-3 ,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-( 1 -&gt;4)-2-acetamido-6-0- benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> VI as solid foam; [OC]D +37 (c 0.1, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.147" epochem-id="EPOCHEM:NEW:COMPOUND:309" name="chloroform" comment="" chebi-id="CHEBI:35255" relevant="false">chloroform</ne>). For <ne type="FORMULA" id="WO2007045192.HC.formula-names.5" epochem-id="EPOCHEM:NEW:FORMULA:74" name="C46H50N2O18" comment="" chebi-id="WO2007045192:360542" relevant="false">C46H50N2O18</ne> calculated: relative molecular mass 918.9, monoisotopic mass 918.3. ESI MS, m/z: 941.5 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.6" epochem-id="EPOCHEM:NEW:FORMULA:74" name="C46H50N2O18" comment="" chebi-id="WO2007045192:360542" relevant="false">C46H50N2O18</ne> (918.9) calculated: 60.13 % C, 5.48 % H, 3.05 % N; found: 60.33 % C, 5.45 % H, 2.86 % N.
Example 7
A solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.214" epochem-id="EPOCHEM:NEW:COMPOUND:1260" name="ben2yl-3,4,6-tri-O-aceryl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-(l-&gt;4)- 2-acetamido-6-O-benzoyl-2-deoxy-3-6&gt;-[l-(R)-(methoxycarbonyl)ethyl-[alpha]-D-glucopyranoside" comment="benzyl-3,4,6-tri-O-aceryl-2-deoxy-2-phtalimido-[beta]-D-glucopyranosyl-(1-&gt;4)- 2-acetamido-6-O-benzoyl-2-deoxy-3-6&gt;-[l-(R)-(methoxycarbonyl)ethyl-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:963288" relevant="true">ben2yl-3,4,6-tri-O-aceryl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-(l-&gt;4)- 2-acetamido-6-O-benzoyl-2-deoxy-3-6&gt;-[l-(R)-(methoxycarbonyl)ethyl-[alpha]-D-glucopyranoside</ne> VI (18.4 g, 20 mmol) in 0.01M <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.88" epochem-id="EPOCHEM:NEW:COMPOUND:770" name="sodium methoxide" comment="" chebi-id="WO2007045192:61066" relevant="false">sodium methoxide</ne> solution in anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.56" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> (500 ml) is left to stand for 48 h at laboratory temperature and the mixture is neutralized by adding of ion exchanger Dowex 50 in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.216" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> cycle. Ion exchanger is filtered off, washed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.57" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> (200 ml) and filtrate was evaporated in vacuum. Evaporated residue is heated under stirring in 0,25M aqueous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.90" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne> solution (550 ml) at 60 &lt;0&gt;C for 3.5 h.
After cooling down to room temperature the mixture is neutralized with ion exchanger Dowex 50 in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.217" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> cycle. Ion exchanger is filtered off, washed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.170" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (100 ml), the eluate was evaporated in vacuum, and the evaporated residue is co-distilled at vacuum with anhydrous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.58" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> (3 x 80 ml). The evaporated residue is dissolved in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.59" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.92" epochem-id="EPOCHEM:NEW:COMPOUND:1223" name="n-butylamine" comment="" chebi-id="WO2007045192:271610" relevant="false">n-butylamine</ne> mixture (4:1, 300 ml) and the solution is heated in pressure tank for 11 h at 85-90 &lt;0&gt;C. After cooling down to room temperature, the mixture is evaporated in vacuum and the residue is extracted with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.130" epochem-id="EPOCHEM:NEW:COMPOUND:866" name="diethyl ether" comment="" chebi-id="CHEBI:35702" relevant="false">diethyl ether</ne> (3 x 150 ml). Insoluble residue is dissolved in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.171" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (250 ml), pH solution is adjusted with formic acid to pH 4 and the solution is applied to ion exchanger Dowex 50 column in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.219" epochem-id="EPOCHEM:COMPOUND:4221" name="ammonium" comment="" chebi-id="CHEBI:28938" relevant="false">ammonium</ne> cycle (800 ml).
The column is washed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.172" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (1500 ml) and product is liberated from ion exchanger washing with 5% aqueous <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.250" epochem-id="EPOCHEM:COMPOUND:3794" name="ammonia" comment="" chebi-id="CHEBI:16134" relevant="false">ammonia</ne> (1000 ml). The eluted fraction was evaporated in vacuum. The obtained <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.220" epochem-id="EPOCHEM:NEW:COMPOUND:1261" name="benzyl-2-amino-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-2-acetamido-2-deoxy-3-O- [l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-amino-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-2-acetamido-2-deoxy-3-O- [1-(R)-carboxyethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:915673" relevant="true">benzyl-2-amino-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-2-acetamido-2-deoxy-3-O- [l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside</ne> VII is N-acetylated without any next purification (see Example 8). An analytical sample of compound VII is prepared on crystallization from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.251" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>; m.p. 183-185 [deg.]C; [[alpha]]D +109 (c 0.2, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.173" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>). For <ne type="FORMULA" id="WO2007045192.HC.formula-names.7" epochem-id="EPOCHEM:NEW:FORMULA:75" name="C24H36N2O12" comment="" chebi-id="WO2007045192:22384" relevant="false">C24H36N2O12</ne> calculated: relative molecular mass 544.6, monoisotopic mass 544.2. ESI MS, m/z: 545.0 [M + H]&lt;+&gt;, 567.3 [M + Na]&lt;+&gt;.
Example 8
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.71" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">Acetic acid</ne> anhydride (20 ml) is stepwise added to a stirred <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.221" epochem-id="EPOCHEM:NEW:COMPOUND:1262" name="benzyl-2-amino-2-deoxy-[beta]- D-glucopyranosyl-(1-&gt;4)-2-acetamido-2-deoxy-3-O-[1-(R)-carboxyethyl-[alpha]-D-glucopyranoside" comment="" chebi-id="WO2007045192:186517" relevant="true">benzyl-2-amino-2-deoxy-[beta]- D-glucopyranosyl-(l--&gt;4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl-[alpha]-D-glucopyranosi- de</ne> VII (obtained in Example 7) solution (160 ml) at room temperature during 15 min. After 30 min the next portion of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.72" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> anhydride is added (20 ml), and the stirring continues for 2 h. The solution was evaporated in vacuum, the evaporated residue is dissolved in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.174" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> and this solution is applied to ion exchanger Dowex 50 column in pyridinium cycle (300 ml). The column is washed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.175" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> (700 ml), and eluted portion was evaporated in vacuum. &lt;'&gt; The residue is lyofilized from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.176" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>. The yield is 7.1 g (60.5 %) of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.222" epochem-id="EPOCHEM:NEW:COMPOUND:1263" name="benzyl-2-acetamido-2- deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl]-[alpha]-D- glucopyranoside" comment="benzyl-2-acetamido-2- deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-2-acetamido-2-deoxy-3-O-[1-(R)-carboxyethyl]-[alpha]-D- glucopyranoside" chebi-id="WO2007045192:148944" relevant="false">benzyl-2-acetamido-2- deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl]-[alpha]-D- glucopyranoside</ne> I, in relation to compound VI; [[alpha]]p + 70 (c 0.2, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.177" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>). For <ne type="FORMULA" id="WO2007045192.HC.formula-names.8" epochem-id="EPOCHEM:NEW:FORMULA:76" name="C26H38N2O13" comment="" chebi-id="WO2007045192:227554" relevant="false">C26H38N2O13</ne> calculated: relative molecular mass 586.6, monoisotopic mass 586.2. ESI MS, m/z: 609.4 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.9" epochem-id="EPOCHEM:NEW:FORMULA:76" name="C26H38N2O13" comment="" chebi-id="WO2007045192:227554" relevant="false">C26H38N2O13</ne> (586.6) calculated: 53.24 % C, 6.53 %H, 4.78 % N; found: 53.05 % C5 6.82 % H5 4.55 % N.
Example 9
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.97" epochem-id="EPOCHEM:NEW:COMPOUND:1227" name="bis(pentafluorophenyl)carbonate" comment="" chebi-id="WO2007045192:981103" relevant="false">Bis(pentafluorophenyl)carbonate</ne> (434 mg, 1.1 mmol) and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.223" epochem-id="EPOCHEM:NEW:COMPOUND:1264" name="4-methylmorfoline" comment="4-methylmorpholine" chebi-id="WO2007045192:834233" relevant="false">4-methylmorfoline</ne> (0.11 ml, 1 mmol) were added to a stirred solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.224" epochem-id="EPOCHEM:NEW:COMPOUND:1265" name="benzyl-2-acetamido-2-deoxy-[beta]-D-gluco- pyranosyl-(l -&gt;4)-2-acetamido-2-deoxy-3-0-[l -(R)~carboxyethyl-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-[beta]-D-gluco- pyranosyl-(1-&gt;4)-2-acetamido-2-deoxy-3-0-[l -(R)-carboxyethyl-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:223544" relevant="true">benzyl-2-acetamido-2-deoxy-[beta]-D-gluco- pyranosyl-(l -&gt;4)-2-acetamido-2-deoxy-3-0-[l -(R)~carboxyethyl-[alpha]-D-glucopyranoside</ne> I (587 mg, 1 mmol) in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.225" epochem-id="EPOCHEM:NEW:COMPOUND:1266" name="iV,iV-dimethylformamide" comment="N, N-difmethylformamide" chebi-id="WO2007045192:569286" relevant="false">iV,iV-dimethylformamide</ne> (4 ml) at room temperature, and the mixture is stirred for one hour. Reaction process is monitored by TLC in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.252" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>. <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.36" epochem-id="EPOCHEM:NEW:COMPOUND:1213" name="dioxan" comment="" chebi-id="WO2007045192:460233" relevant="false">Dioxan</ne> (20 ml) is then added and the mixture is lyofilized. A repeated lyofilization of the product from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.37" epochem-id="EPOCHEM:NEW:COMPOUND:1213" name="dioxan" comment="" chebi-id="WO2007045192:460233" relevant="false">dioxan</ne> afforded 723 mg (96 %) <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.226" epochem-id="EPOCHEM:NEW:COMPOUND:1267" name="benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetami- do-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:798273" relevant="true">benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-2-acetami- do-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside</ne> X that is, without any purification, condensed with a <ne id="WO2007045192.HC.class-names.97" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> component (see Example 10). For (<ne type="FORMULA" id="WO2007045192.HC.formula-names.16" epochem-id="EPOCHEM:NEW:FORMULA:82" name="C32H37F5N2O1S" comment="" chebi-id="WO2007045192:138227" relevant="false">C32H37F5N2O1S</ne>) calculated: relative molecular mass 752.6, monoisotopic mass 752.2. ESI MS, m/z: 775.6 [M + Na]&lt;+&gt;.
Example 10
A solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.247" epochem-id="EPOCHEM:NEW:COMPOUND:2055" name="L-Ala-D-iso-Gln-OBn" comment="" chebi-id="WO2007045192:962811" relevant="false">L-Ala-D-iso-Gln-OBn</ne> (615 mg, 2 mmol) and iV-methylmorfoline (0.30 ml, 2.73 mmol) in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.218" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> (6 ml) at 0 &lt;0&gt;C is added to a stirred solution of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.227" epochem-id="EPOCHEM:NEW:COMPOUND:1268" name="ben2yl-2-acetamido- 2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorofenoxycar- bonyl)ethyl]-[alpha]-D-glucopyranoside" comment="benzyl-2-acetamido- 2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorofenoxycarbonyl)ethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:799933" relevant="true">ben2yl-2-acetamido- 2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorofenoxycar- bonyl)ethyl]-[alpha]-D-glucopyranoside</ne> X (753 mg, 1 mmol) and the stirring continues for 20 h at +5 &lt;0&gt;C. The mixture was evaporated in vacuum, the evaporated residue is co-distilled in vacuum with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.73" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> (10 ml), and the residue is chromatographed on <ne type="CHEMICAL" id="WO2007045192.HC.substance-names.3" epochem-id="EPOCHEM:NEW:SUBSTANCE:326" name="silica gel" comment="" chebi-id="WO2007045192:415358" relevant="false">silica gel</ne> Cl 8 column in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.178" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.60" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> system (linear gradient: 0-&gt;30 %, 60 min). Lyofilization of evaporated residue of homogenous fraction from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.179" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> afforded 744 mg (85.0 %) <ne id="WO2007045192.HC.class-names.73" epochem-id="EPOCHEM:NEW:CLASS:803" name="benzyl ester" comment="" chebi-id="WO2007045192:467443" relevant="false" type="CLASS">benzyl ester</ne> of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.228" epochem-id="EPOCHEM:NEW:COMPOUND:1269" name="N-{2-0-[benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-2-acetamido-2,3- dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine" comment="" chebi-id="WO2007045192:360129" relevant="true">N-{2-0-[benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-2-acetamido-2,3- dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine</ne> of formulae IX (wherein X is <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.248" epochem-id="EPOCHEM:NEW:COMPOUND:2055" name="L-Ala-D-iso-Gln-OBn" comment="" chebi-id="WO2007045192:962811" relevant="false">L-Ala-D-iso-Gln-OBn</ne>); [[alpha]]D +50 (c 0.4, 50% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.61" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.180" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>). For (<ne type="FORMULA" id="WO2007045192.HC.formula-names.10" epochem-id="EPOCHEM:NEW:FORMULA:77" name="C41H57N5O16" comment="" chebi-id="WO2007045192:585625" relevant="false">C41H57N5O16</ne>) calculated: relative molecular mass 875.9, monoisotopic mass 875.4. ESI MS, m/z: 898.4 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.11" epochem-id="EPOCHEM:NEW:FORMULA:78" name="C4IH57N5O16" comment="C41H57N5O16" chebi-id="WO2007045192:783610" relevant="false">C4IH57N5O16</ne> (875.9) calculated: 56.22 % C5 6.56 % H, 8.00 % N; found: 55.81 % C5 6.60 % H5 7.90 % N. Example 11
<ne id="WO2007045192.HC.class-names.74" epochem-id="EPOCHEM:NEW:CLASS:803" name="benzyl ester" comment="" chebi-id="WO2007045192:467443" relevant="false" type="CLASS">Benzyl ester</ne> of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.229" epochem-id="EPOCHEM:NEW:COMPOUND:1270" name="N-{2-O-[benzyl-2-acetamido-2-deoxy-[beta]-D-gluco[rho]yranosyl-(l-&gt;4)-2- acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine" comment="N-{2-O-[benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)-2- acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine" chebi-id="WO2007045192:329168" relevant="true">N-{2-O-[benzyl-2-acetamido-2-deoxy-[beta]-D-gluco[rho]yranosyl-(l-&gt;4)-2- acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine</ne> XI (876 mg, 1 mmol) is hydrogenolyzed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.256" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> on 5% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.111" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> <ne type="ONT" id="WO2007045192.HC.class-names.84" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> on charcoal (300 mg) in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.74" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> (14 ml) at room temperature 48 h. After washing out of apparatus with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.260" epochem-id="EPOCHEM:COMPOUND:7100" name="argon" comment="" chebi-id="CHEBI:33311" relevant="false">argon</ne>, the <ne type="ONT" id="WO2007045192.HC.class-names.85" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> is filtered off, washed with 50% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.75" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> (30), and filtrate is evaporated in vacuum. The evaporated residue is chromatographed at <ne type="CHEMICAL" id="WO2007045192.HC.substance-names.4" epochem-id="EPOCHEM:NEW:SUBSTANCE:326" name="silica gel" comment="" chebi-id="WO2007045192:415358" relevant="false">silica gel</ne> Cl 8 column in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.181" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>- <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.62" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> system (linear gradient: 0-&gt;20 %, 60 min). Lyofilization of the residue of homogenous fraction from <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.182" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> afforded 612 mg (88 %) <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.230" epochem-id="EPOCHEM:NEW:COMPOUND:1271" name="2-acetamido-2-deoxy-[beta]-D- glucopyranosyl-(l--&gt;4)-iV-acetylmuramyl-L-alanyl-D-isoglutamm" comment="2-acetamido-2-deoxy-[beta]-D- glucopyranosyl-(1-&gt;4)-N-acetylmuramyl-L-alanyl-D-isoglutamin" chebi-id="WO2007045192:466641" relevant="true">2-acetamido-2-deoxy-[beta]-D- glucopyranosyl-(l--&gt;4)-iV-acetylmuramyl-L-alanyl-D-isoglutamm</ne> (<ne id="WO2007045192.HC.class-names.48" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne>) IX (in which X is <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.243" epochem-id="EPOCHEM:NEW:COMPOUND:2053" name="L-Ala-D-iso-Gln-OH" comment="" chebi-id="WO2007045192:637657" relevant="false">L-Ala-D-iso-Gln-OH</ne>); [[alpha]]D -3 (c 0.3, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.183" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>); lit.&lt;27&gt; [[alpha]]D -2 (c 1.0, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.184" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>). For (<ne type="FORMULA" id="WO2007045192.HC.formula-names.12" epochem-id="EPOCHEM:NEW:FORMULA:79" name="C27H45N5O16" comment="" chebi-id="WO2007045192:640673" relevant="false">C27H45N5O16</ne>) calculated: relative molecular mass 695.7, monoisotopic mass 695.3. ESI MS, m/z: 718.5 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.13" epochem-id="EPOCHEM:NEW:FORMULA:79" name="C27H45N5O16" comment="" chebi-id="WO2007045192:640673" relevant="false">C27H45N5O16</ne> (695.7) calculated: 46.62 % C, 6.52 % H, 10.07 % N; found: 46.21 % C, 6.85 % H, 9.96 % N.
Example 12
<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.231" epochem-id="EPOCHEM:NEW:COMPOUND:1272" name="Ben2yl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l- &gt;4)-2-acetamido-2-deoxy-3-O- [l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside" comment="Benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1- &gt;4)-2-acetamido-2-deoxy-3-O- [l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside" chebi-id="WO2007045192:226640" relevant="true">Ben2yl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l- &gt;4)-2-acetamido-2-deoxy-3-O- [l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside</ne> I (5.9 g, 10 mmol) is hydrogenolyzed with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.257" epochem-id="EPOCHEM:COMPOUND:7665" name="hydrogen" comment="" chebi-id="CHEBI:24634" relevant="false">hydrogen</ne> over 5% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.112" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> <ne type="ONT" id="WO2007045192.HC.class-names.86" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> on charcoal (3 g) in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.76" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> (140 ml) at room temperature for 48 h.
The apparatus was washed out with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.261" epochem-id="EPOCHEM:COMPOUND:7100" name="argon" comment="" chebi-id="CHEBI:33311" relevant="false">argon</ne>, the <ne type="ONT" id="WO2007045192.HC.class-names.87" epochem-id="EPOCHEM:NEW:CLASS:581" name="catalyst" comment="" chebi-id="CHEBI:35223" relevant="false">catalyst</ne> was filtered off, washed with 50% <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.77" epochem-id="EPOCHEM:COMPOUND:445" name="acetic acid" comment="" chebi-id="CHEBI:15366" relevant="false">acetic acid</ne> (300 ml), and filtrate was evaporated in vacuum. The evaporated residue is cliromatographed on <ne type="CHEMICAL" id="WO2007045192.HC.substance-names.5" epochem-id="EPOCHEM:NEW:SUBSTANCE:326" name="silica gel" comment="" chebi-id="WO2007045192:415358" relevant="false">silica gel</ne> Cl 8 column in <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.185" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>-<ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.63" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> system (linear gradient: 0-&gt;20 %, 60 min). Lyofilization of the evaporated residue of homogenous fraction afforded 4667 mg (94 %) of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.232" epochem-id="EPOCHEM:NEW:COMPOUND:1273" name="2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-iV- acetylmurarnic acid" comment="2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-N- acetylmurarnic acid" chebi-id="WO2007045192:925733" relevant="true">2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l--&gt;4)-iV- acetylmurarnic acid</ne> VIII; [[alpha]]D +5 (c 0.3, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.186" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>); lit.&lt;29&gt; [[alpha]]D +4 (c 1.0, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.187" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>). For (<ne type="FORMULA" id="WO2007045192.HC.formula-names.14" epochem-id="EPOCHEM:NEW:FORMULA:80" name="C1PHs2N2O13" comment="C19H32N2O13" chebi-id="WO2007045192:786503" relevant="false">C1PHs2N2O13</ne>) calculated: relative molecular mass 496.5, monoisotopic mass 496.2. ESI MS, m/z: 519,4 [M + Na]&lt;+&gt;. For <ne type="FORMULA" id="WO2007045192.HC.formula-names.15" epochem-id="EPOCHEM:NEW:FORMULA:81" name="C19H32N2O13" comment="" chebi-id="WO2007045192:341089" relevant="false">C19H32N2O13</ne> (496,5) calculated: 45.97 % C5 6.50 % H, 5.64 % N; found: 45.57 % C, 6.72 % H, 5.43 % N.
The structures of all above given compounds are unambiguously proved by their &lt;1&gt;H a &lt;13&gt;C NMR spectra. Industrial utility
The compounds of the present invention can be used in basic research, pharmaceutical industry and both in human and veterinary medicine.
Formulae:
</P>
<P>[0073]
EMI18.1
</P>
<P>[0074]
EMI18.2
</P>
<P>[0075]
EMI18.3
</P>
<P>[0076]
EMI18.4
IV
EMI19.1
V
</P>
<P>[0079]
EMI19.2
</P>
<P>[0080]
EMI19.3
VII
</P>
<P>[0081]
EMI19.4
</P>
<P>[0082]
EMI19.5
EMI20.1
</P>
<P>[0083]
EMI20.2
Xl
REFERENCES
</P>
<P>1. Adam A.Adam A., in: Synthetic Adjuvants, p. 1. John Wiley and Sons, New York 2004.
</P>
<P>2. Andronova T.M., Ivanov V.T.: Sov. Nedical. Review D. Immunology 1991, 4, 1.
</P>
<P>3. Azuma L: Vaccine 1992, 10, 1000.
</P>
<P>4. Baschang G.: Tetrahedron 1989, 45, 6331.
</P>
<P>5. Hiraoka A., Masaoka T., Satoh T., Ota K., Oyama A., Horiuchi A., Hasegawa H., Nagai K., Kosaki M., Kanemaru A.: Arzneimittel-Forschung 1988, 55,1499.
</P>
<P>6. Furuse K., Sakuma A. : Arzneimittel-Forschung 1989, 39,915.
</P>
<P>7. Khaidukov S., V, Komaleva R.L., Nesmeyanov V.A. : International Journal of Immunopharmacology 1995, 77,903.
</P>
<P>8. Yoo Y.C., Yoshimatsu K., Koike Y., Hatsuse R., Yamanishi K., Tanishita O., Arikawa J., Azuma L: Vaccine 1998, 16, 216.
</P>
<P>9. Namba K., Nakajima R., Otani T., Azuma I. : Vaccine 1996, 7^,1149.
</P>
<P>10. Niki Y., Tatara O.: Advances in Experimental Medicine and Biology 1992, 319,185.
</P>
<P>11. Yoo Y.C., Park S. Y., Lee K.B., Azuma L: Journal of Microbiology and Biotechnology 2000, 10, 399.
</P>
<P>12. Aston R. ((Biokine Technology Ltd., UK): WO 92-GB2137.9310148;
</P>
<P>13. Aston R., Maitchouk L, Andronova T.M. ((Peptech (Uk) Limited, UK): WO 95- GB2237.9609063;
</P>
<P>14. Vosika GJ., Cornelius D. A., Bennek J.A., Sadlik J.R., Gilbert CW. : MoI. Biother. 1990, 2, 50.
</P>
<P>15. Vosika G. J., Cornelius D. A., Gilbert C. W., Sadlik J.R., Bennek J. A., Doyle A., Hertsgaard D.: J. Immunother. 1991, 10, 256.
</P>
<P>16. Fast DJ., Vosika G.J.: Vaccine 1997, 15, 1748. W
</P>
<P>17. Vosika GJ. ((Endorex Corporation, USA): WO 97-US8146.9743308;
</P>
<P>18. M.F.Powell, M. J. Newman Eds.Vaccine design, (M.F.Powell, M. J. Newman Eds.), p. 141. Plenum Press, New York 1995.
</P>
<P>19. Banoub J., Boullanger P., Lafont D. : Chemical Reviews 1992, 92, 1167.
</P>
<P>20. Garegg PJ.: Advances in Carbohydrate Chemistry and Biochemistry, VoI 52 1997, 52, 179.
</P>
<P>21. Paulsen H.: Angewandte Chemie-International Edition in English 1982, 21, 155.
</P>
<P>22. Schmidt R.R., Kinzy W.: Advances in Carbohydrate Chemistry and Biochemistry, VoI 50 1994, 50, 21.
</P>
<P>23. Sinay P. : Pure and Applied Chemistry 1991 , 63, 519.
</P>
<P>24. Inage M., Imoto M., Kambayashi Y., Kusumoto S., Shiba T.: Tetrahedron Letters 1980, 21, 3767.
</P>
<P>25. Kusumoto S., Yamamoto K., Imoto M., Inage M., Tsujimoto M., Kotani S., Shiba T.: Bulletin of the Chemical Society of Japan 1986, 59, 1411.
</P>
<P>26. Durette P.L., Meitzner E.P.: Carbohydr. Res. 1981, 89, 279.
</P>
<P>27. Kiso M., Kaneda Y., Shimizu R., Hasegawa A., Azuma L: Carbohydr. Res. 1982, 104,
</P>
<P>253.
</P>
<P>28. Durette PX. ((Merck and Co., Inc. USA): EP 80-400566.18901 ;
</P>
<P>29. Kantoci D., Keglevic D., Derome A.E.: Carbohydr. Res. 1987, 162, 227.
</P>
<P>30. Kusumoto S., Imoto M., Ogiku T., Shiba T.: Bulletin of the Chemical Society of Japan 1986, 59, 1419.
</P>
<P>31. Termin A., Schmidt R.R. : Liebigs Annalen der Chemie 1989,789.
</P>
<P>32. Termin A., Schmidt R.R.: Liebigs Annalen der Chemie 1992,527.
</P>
<P>33. Vosika GJ. ((Endorex Corporation, USA): WO 96-US 15391.9712894; 34. Bezrukova EJ. ((Bezrukov, Mikhail Vasilievich Russia and Bezrukova, Elena Jurievna): WO 96-RU254.9710259;
</P>
<P>35. Bistricenko A. ((Bistricenko, Andrejs Latvia and Jerniolajevs, Jevgenijs): LV 94- 940018.10963;
</P>
<P>36. Vosika GJ. ((ImmunoTherapeutics, Inc. USA): WO 89-US302.9000396;
</P>
<P>37. Farkas J., Ledvina M., Brokes J., Jezek J., Zajicek J., Zaoral M.: Carbohydr. Res. 1987, 163, 63.
</P>
<P>38. Vesely J., Ledvina M., Jindfich J., Saman D., Trnka T.: Collect. Czech. Chem. Commun. 2003, 68, 1264.
</P>
<P>39. Ledvina M., Farkas J., Zajicek J., Jezek J., Zaoral M.: Collect. Czech. Chem. Commun. 1989, 54, 2784.
</P>
<P>40. Zaoral M., Jezek J., Straka R., Masek K.: Collect. Czech. Chem. Commun. 1978, 43, 1977.
</P>
<P>41. Keglevic D., Pongracic M.: Carbohydr. Res. 1984, 135, 85.
</P>
<P>42. Flowers H.M., Jeanloz R.: Jouranal of Organic Chemistry 1963, 28, 2983.
</P>
<P>43. Arita H., Fukukawa K., Matsushima Y. : Bulletin of the Chemical Society of Japan 1972, 45, 3611.
</P>
<P>44. Hasegawa A., Kaneda Y., Amano M., Kiso M., Azuma L: Agricultural and Biological Chemistry 1978, 42, 2187 '.
Claims
</P>
<P>1. <ne id="WO2007045192.HC.class-names.19" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">Disaccharide</ne> synthon I
EMI24.1
</P>
<P>2. Method of synthesis of compound I according to the claim 1, comprising as glycosyl acceptor the derivative of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.7" epochem-id="EPOCHEM:COMPOUND:260" name="muramic acid" comment="" chebi-id="CHEBI:28118" relevant="false">muramic acid</ne> of formula II
EMI24.2
which is prepared from compound III
EMI24.3
which is 3-O-alkylated on treatment with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.10" epochem-id="EPOCHEM:NEW:COMPOUND:1195" name="2-bromopropionic acid" comment="" chebi-id="WO2007045192:71889" relevant="true">2-bromopropionic acid</ne> and then transformed on esterif[iota]cation to compound IV
EMI24.4
IV
which is then converted by splitting off of the <ne type="LIGAND" id="WO2007045192.HC.ligand-names.33" epochem-id="EPOCHEM:NEW:LIGAND:625" name="isopropylidene" comment="" chebi-id="CHEBI:29858" relevant="false">isopropylidene</ne> group to compound V
EMI25.1
which is then transformed on partial benzoylation with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.241" epochem-id="EPOCHEM:NEW:COMPOUND:2052" name="benzoylimidazole" comment="" chebi-id="WO2007045192:497595" relevant="false">benzoylimidazole</ne> to glycosyl acceptor of formula II
EMI25.2
Il
which on reaction with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.11" epochem-id="EPOCHEM:NEW:COMPOUND:1196" name="3,4,6-tri-(9-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl- bromide" comment="" chebi-id="WO2007045192:522248" relevant="true">3,4,6-tri-(9-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl- bromide</ne>, as <ne type="ONT" id="WO2007045192.HC.class-names.3" epochem-id="EPOCHEM:NEW:CLASS:285" name="glycosyl donor" comment="" chebi-id="WO2007045192:220621" relevant="false">glycosyl donor</ne>, affords <ne id="WO2007045192.HC.class-names.20" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> VI
EMI25.3
Vl
which is then transformed by gradual removing of protecting groups, sensitive to alkali, e.g. <ne type="LIGAND" id="WO2007045192.HC.ligand-names.27" epochem-id="EPOCHEM:NEW:LIGAND:160" name="acetyl" comment="" chebi-id="WO2007045192:727560" relevant="false">acetyl</ne>, <ne type="LIGAND" id="WO2007045192.HC.ligand-names.25" epochem-id="EPOCHEM:NEW:LIGAND:363" name="benzoyl" comment="" chebi-id="CHEBI:22733" relevant="false">benzoyl</ne>, <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.84" epochem-id="EPOCHEM:NEW:COMPOUND:1222" name="methyl ester" comment="" chebi-id="WO2007045192:626249" relevant="false">methyl ester</ne> and <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.86" epochem-id="EPOCHEM:COMPOUND:4551" name="phthalimide" comment="" chebi-id="CHEBI:38817" relevant="false">phthalimide</ne> groups, to compound VII
EMI25.4
VII
which on N&lt;~&gt;-acetylation affords <ne id="WO2007045192.HC.class-names.21" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon of formula I.
</P>
<P>3. Use of <ne id="WO2007045192.HC.class-names.22" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon I according to the claims 1 and 2 for the synthesis of <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.12" epochem-id="EPOCHEM:NEW:COMPOUND:1197" name="2- acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)--V-acetylniuramic acid" comment="2- acetamido-2-deoxy-[beta]-D-glucopyranosyl-(1-&gt;4)-N-acetylmuramic" chebi-id="WO2007045192:916079" relevant="true">2- acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-&gt;4)--V-acetylniuramic acid</ne> VIII
EMI26.1
which is obtained on hydrogenolytic removing of <ne type="LIGAND" id="WO2007045192.HC.ligand-names.32" epochem-id="EPOCHEM:NEW:LIGAND:549" name="benzyl" comment="" chebi-id="CHEBI:22744" relevant="false">benzyl</ne> protecting group.
</P>
<P>4. Use of <ne id="WO2007045192.HC.class-names.23" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon I according to the claims 1 and 2 for the synthesis of <ne id="WO2007045192.HC.class-names.29" epochem-id="EPOCHEM:NEW:CLASS:997" name="muramyl glycopeptides" comment="" chebi-id="WO2007045192:575300" relevant="false" type="CLASS">muramyl glycopeptides</ne> based on a <ne id="WO2007045192.HC.class-names.49" epochem-id="EPOCHEM:NEW:CLASS:999" name="GMDP" comment="" chebi-id="WO2007045192:580823" relevant="false" type="CLASS">GMDP</ne> molecule of general formula IX
EMI26.2
in which X is a <ne id="WO2007045192.HC.class-names.98" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> residue, wherein the <ne id="WO2007045192.HC.class-names.24" epochem-id="EPOCHEM:NEW:CLASS:286" name="Disaccharide" comment="" chebi-id="CHEBI:36233" relevant="true" type="CLASS">disaccharide</ne> synthon I is transformed on treatment with <ne type="CHEMICAL" id="WO2007045192.HC.chemical-names.13" epochem-id="EPOCHEM:NEW:COMPOUND:1198" name="bis(pentafluoro- phenyl)carbonate" comment="" chebi-id="WO2007045192:512307" relevant="true">bis(pentafluoro- phenyl)carbonate</ne> to compound X
EMI26.3
which is then on treatment with <ne id="WO2007045192.HC.class-names.99" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> component transformed to compound of general formula XI
EMI27.1
Xl
in which X is a <ne id="WO2007045192.HC.class-names.100" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> residue, and this compound on removing of protecting groups, under conditions given by their character, affords compound X
EMI27.2
in which X is a <ne id="WO2007045192.HC.class-names.101" epochem-id="EPOCHEM:NEW:CLASS:8" name="peptide" comment="" chebi-id="CHEBI:16670" relevant="false" type="CLASS">peptide</ne> residue.
</P></DIV>
<DIV><P>
</P></DIV>
</BODY>
</PAPER>
